scholarly journals Is salvage surgery for recurrent non-small-cell lung cancer after definitive non-operative therapy associated with reasonable survival?: Table 1:

2015 ◽  
Vol 21 (5) ◽  
pp. 682-684 ◽  
Author(s):  
Waldemar Schreiner ◽  
Wojciech Dudek ◽  
Horia Sirbu
2020 ◽  
Vol 31 (6) ◽  
pp. 892-894
Author(s):  
Keiji Yamanashi ◽  
Masatsugu Hamaji ◽  
Yukinori Matsuo ◽  
Noriko Kishi ◽  
Toyofumi Fengshi Chen-Yoshikawa ◽  
...  

Abstract There is dearth of data regarding the long-term survival outcomes of salvage surgery after stereotactic body radiotherapy for early-stage non-small-cell lung cancer, as previous studies have included a short follow-up period. There is also scarce information on the management of re-relapse in previous studies. This study examined the long-term survival outcomes of patients who underwent salvage surgery for isolated local relapse (LR). We reviewed consecutive patients who underwent salvage surgery for isolated LR after stereotactic body radiotherapy for early-stage non-small-cell lung cancer between 1999 and 2015. All patients were followed up until death or at least 5 years from salvage surgery. Twelve patients were included for analysis. The median follow-up from isolated LR was 62.4 (range: 14.3–152.1) months. The 5-year overall survival rate was 58.3%, updated from 79.5% in our previous report. During the interim, new re-relapses did not occur, whereas there were 5 additional deaths. The median survival after re-relapse was 32.6 months. Our follow-up report confirmed that our patient selection for salvage surgery appeared to be appropriate and that long-term follow-up is required to assess the outcomes of patients undergoing salvage surgery. Long-term follow-up would provide detailed information on late re-relapses, treatment and outcomes of re-relapses and mortality from any causes.


2020 ◽  
Vol 9 (12) ◽  
pp. 3881
Author(s):  
Shigeki Suzuki ◽  
Taichiro Goto

With the development of systemic treatments with high response rates, including tyrosine kinase inhibitors and immune checkpoint inhibitors, some patients with unresectable lung cancer now have a chance to undergo radical resection after primary treatment. Although there is no general consensus regarding the definition of “unresectable” in lung cancer, the term “resectable” refers to technically resectable and indicates that resection can provide a favorable prognosis to some extent. Unresectable lung cancer is typically represented by stage III and IV disease. Stage III lung cancer is a heterogeneous disease, and in some patients with technically resectable non-small cell lung cancer (NSCLC), multimodality treatments, including induction chemoradiotherapy followed by surgery, are the treatments of choice. The representative surgical intervention for unresectable stage III/IV NSCLC is salvage surgery, which refers to surgical treatment for local residual/recurrent lesions after definitive non-surgical treatment. Surgical intervention is also used for an oligometastatic stage IV NSCLC. In this review, we highlight the role of surgical intervention in patients with unresectable NSCLC, for whom an initial complete resection is technically difficult. We further describe the history of and new findings on salvage surgery for unresectable NSCLC and surgery for oligometastatic NSCLC.


2016 ◽  
Vol 11 (1) ◽  
Author(s):  
Naomi E. Verstegen ◽  
Alexander P. W. M. Maat ◽  
Frank J. Lagerwaard ◽  
Marinus A. Paul ◽  
Michel I Versteegh ◽  
...  

Haigan ◽  
2019 ◽  
Vol 59 (2) ◽  
pp. 163-167
Author(s):  
Masatoshi Kanayama ◽  
Toshihiro Osaki ◽  
Yukiko Fukuichi ◽  
Kenichi Kobayashi ◽  
Manabu Yasuda ◽  
...  

2019 ◽  
Vol 49 (4) ◽  
pp. 389-392 ◽  
Author(s):  
Keita Nakanishi ◽  
Tetsuya Mizuno ◽  
Noriaki Sakakura ◽  
Hiroaki Kuroda ◽  
Junichi Shimizu ◽  
...  

Author(s):  
Katarzyna Furrer ◽  
Raphael S Werner* ◽  
Sven Hillinger ◽  
Didier Schneiter ◽  
Ilhan Inci ◽  
...  

2021 ◽  
Vol 16 (10) ◽  
pp. S1051-S1052
Author(s):  
K. Furrer ◽  
R. Werner ◽  
A. Curioni-Fontecedro ◽  
S. Hillinger ◽  
D. Schneiter ◽  
...  

2018 ◽  
Vol 10 ◽  
pp. 175883591880415 ◽  
Author(s):  
Chris Dickhoff ◽  
Rene H. J. Otten ◽  
Martijn W. Heymans ◽  
Max Dahele

Background: Once recurrent or persistent locoregional tumour after radical chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) is identified, few curative-intent treatment options are available. Selected patients might benefit from surgical salvage. We performed a systematic review of the available literature for this emerging treatment option. Methods: A systematic literature search was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Publications about persistent or (locoregional) recurrent disease after radical/definitive CRT for locally advanced non-small cell lung cancer were identified. Results: Eight full papers were found, representing 158 patients. All were retrospective series and data were heterogeneous: definition and indication for salvage surgery varied and the median time from radiotherapy to surgery was 4.1–33 months. Complete resection (R0) was achieved in 85–100%, with vital tumour in 61–100%. A large number of pneumonectomies were performed, and additional structures were often resected. Where reported, 90-day mortality was 0–11.4%. Reported survival metrics varied but included median overall survival 9–46 months and 5-year survival 20–75%. Conclusion: There are limited, low-level, heterogeneous data in support of salvage surgery after radical CRT. Based on this, perioperative mortality appears acceptable and long-term survival is possible in (highly) selected patients. In suitable patients (fit, no distant metastases, tumour appears completely resectable and preferably with confirmed viable tumour), this treatment option should be discussed in an experienced multidisciplinary lung cancer team.


Sign in / Sign up

Export Citation Format

Share Document